about rapport

We are a clinical-stage biopharmaceutical company focused on the discovery and development of a portfolio of precision small molecule product candidates that we believe has the potential to transform the standard of care of many central nervous system (CNS) disorders.

Our founders uncovered the detailed workings of receptors in the brain, allowing us to map and target certain neuronal receptor complexes. These receptors are made up of assemblies of proteins, including receptor associated proteins (RAPs), which play crucial roles in regulating receptor expression and function. Our pioneering discoveries related to RAP function and structure form the basis of our RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates.

Most neuroscience drugs lack specificity, meaning they bind to target receptors throughout the brain, and often result in intolerable side effects. Built on our deep expertise in RAP biology, we can develop CNS drugs that are specific for receptor variants and brain regions associated with certain diseases.